What Servier Australia does

Servier Australia, operating as Servier Laboratories (Aust.) Pty Ltd, is the Australian and New Zealand subsidiary of the France-headquartered Servier Group, an international pharmaceutical company governed by a non-profit foundation. Established in Australia in 1966 and headquartered in Hawthorn, Melbourne, the company develops, markets, and distributes prescription medicines across four therapeutic areas: Oncology, Neuroscience, Immuno-inflammation, and Cardio-metabolism. Its Australian product portfolio includes cardiovascular treatments (Coveram, Coralan), diabetes medications (Ardix Gliclazide MR), and the recently PBS-listed VORANIGO (vorasidenib), approved from 1 August 2026 as the first new treatment in over 20 years for Grade 2 IDH-mutant astrocytoma or oligodendroglioma.

The business operates a traditional pharma go-to-market: field sales representatives engage GPs and specialists directly, supported by the MyServier HCP portal (educational content, webinars, podcasts, BP monitoring resources), a medical information helpline (1800 153 590), and clinical workflow integrations (SQL queries for Best Practice medical software to identify hypertensive patients). Distribution flows through Australia's PBS for subsidized products and standard pharmacy networks post-prescription. Marketing spans the company website, LinkedIn, Facebook, and collaborative content partnerships such as the Confident Conversations YouTube series with TheCloudGP and youth charity 20Talk. Servier Australia also supports the National Hypertension Taskforce roadmap to reach 70% blood pressure control in Australia by 2030.

Revenue flows from one-time license sales of proprietary brand-name pharmaceuticals and generic products, with PBS reimbursement for listed products such as VORANIGO. The subsidiary employs 11-50 staff in Australia and operates a wholly-owned New Zealand subsidiary (Servier Laboratories NZ Limited, Auckland). Parent Group revenue was €4.9 billion in FY2021/2022, with 21,400 employees across 150+ countries and over 20% of brand-name revenue reinvested in R&D annually.

Name

Servier Australia

Legal name

Servier Laboratories (Aust.) Pty Ltd

Website

https://servier.com.au

Company type

Private

Founded year

1966

Operating status

Operating

Headcount range

11–50 employees

Short description

Servier Australia is the Australian subsidiary of France's Servier Group, developing and distributing prescription medicines across Oncology, Neuroscience, Immuno-inflammation, and Cardio-metabolism to Australian and New Zealand patients via PBS reimbursement, field sales, and HCP digital engagement platforms.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Prescription pharmaceuticals
• Cardio-metabolic medicines
• Oncology therapeutics
• Neuroscience treatments
• Specialty pharmaceuticals

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Brand-name pharmaceuticals: Servier develops and sells proprietary pharmaceutical products under its own brand across four therapeutic areas (Oncology, Neuroscience, Immuno-inflammation, Cardio-metabolism). Revenue from brand-name medicines was €3.7 billion for 2021/2022.
2. Generic pharmaceuticals: Servier also engages in generic drug activities, generating €1.2 billion in revenue for 2021/2022.
3. PBS-listed specialty oncology drug (VORANIGO): VORANIGO (vorasidenib) listed on Australia's Pharmaceutical Benefits Scheme from August 2026 for eligible patients with Grade 2 IDH-mutant astrocytama or oligodendroglioma, providing government-reimbursed access.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Servier Australia develops, manufactures, and distributes proprietary prescription pharmaceutical medicines across four therapeutic areas: Oncology (notably VORANIGO/vorasidenib for rare brain cancers), Neuroscience (depression and anxiety treatments), Immuno-inflammation, and Cardio-metabolism (hypertension and cardiovascular products such as Coveram and Coralan, plus diabetes treatment Ardix Gliclazide MR). The company supports its medicines with healthcare professional education via the MyServier portal, patient education resources, and clinical tools such as downloadable SQL queries for Best Practice medical software. Products are distributed across Australia and New Zealand, with PBS-listed medicines receiving government reimbursement.

Product overview

Servier Australia offers a portfolio of pharmaceutical products across four therapeutic areas: Cardiovascular (including Coveram, Coralan), Diabetes (including Ardix Gliclazide MR), Neuropsychiatry, and Oncology. The company focuses on researching, developing, and fine-tuning innovative medicines, with recent addition of VORANIGO® (vorasidenib) for brain cancer treatment. Products are distributed across Australia and New Zealand, with recent PBS listing providing clinicians with targeted treatment options for rare brain cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• VORANIGO (vorasidenib) Targeted oral therapy for adults and adolescents aged 12 and older with Grade 2 IDH-mutant astrocytoma or oligodendroglioma, a rare and previously underserved brain cancer. It is PBS-listed in Australia from August 2026 and is intended for prescription by oncology specialists.
• Ardix Gliclazide MR Gliclazide modified-release oral hypoglycaemic medication for the management of type 2 diabetes, prescribed by GPs and specialists in Australia.
• Coralan (ivabradine) Ivabradine-based cardiovascular medication used for the treatment of chronic heart failure and stable angina, prescribed by cardiologists and GPs.
• Coveram (perindopril + amlodipine) Fixed-dose combination of perindopril (ACE inhibitor) and amlodipine (calcium channel blocker) used for the treatment of hypertension and associated cardiovascular conditions, prescribed by GPs and specialists.

Quantifiable outcome

• VORANIGO is the first new treatment option in more than 20 years approved for Grade 2 IDH-mutant astrocytoma or oligodendroglioma
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• National Hypertension TaskforcecoreStrategic or Co-development Partner · 9 October 2024Servier Australia supports the National Hypertension Taskforce's mission to improve Australia's blood pressure control rate to 70% by 2030. The partnership involves co-development of patient infographics addressing common questions about hypertension, supporting healthcare professional education through MyServier, and participating in the three-pillar strategy focusing on prevention, detection, and effective treatment.
• TheCloudGPcoreGTM or Marketing Partner · 10 July 2024Servier Australia partnered with TheCloudGP (founded by Dr. Shiromi Wimalaguna) and 20Talk to produce the 'Confident Conversations: Talking Mental Health with Your GP' YouTube series. This collaboration provides practical mental health guidance for young Australians, addressing stigma around mental health consultations with general practitioners. The series includes video content on preparing for GP appointments, Mental Health Care Plan consultations, and maintaining momentum after appointments.
• 20TalkcoreGTM or Marketing Partner · 10 July 202420Talk, a youth charity focused on mental health for young adults aged 18-30, collaborated with Servier Australia and TheCloudGP on the Confident Conversations YouTube series. 20Talk's mission is to be the most relatable mental health charity of the 21st century, challenging the status quo and redefining mental health education. The partnership leverages 20Talk's youth engagement expertise with Servier's pharmaceutical resources.

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Mundipharma Australia: Australia subsidiary of a privately-held international pharmaceutical group selling prescription medicines in pain, oncology, and consumer health, comparable as a privately-owned pharma distributor serving Australian GPs and specialists.
• Mayne Pharma Group: Australia-headquartered specialty pharmaceutical company marketing branded and generic prescription medicines across multiple therapeutic areas, directly comparable as a domestically-distributed pharma operator with multi-indication portfolios.
• Aspen Pharmacare Australia: Australian subsidiary of a global specialty pharmaceutical group distributing branded and generic prescription products through pharmacy channels, comparable as a multi-indication pharma distributor with PBS exposure.
• Boehringer Ingelheim Australia: Australian arm of a major privately-held global pharmaceutical company with strong cardiovascular, respiratory, and metabolic franchises, directly comparable as a foundation/family-controlled pharma competitor operating in Servier's core therapy areas.

Broad incumbents

• Roche Products Australia: Australian arm of a global pharmaceutical leader with deep oncology and neuroscience franchises, providing a benchmark for specialty oncology launches such as Servier's VORANIGO.
• Bayer Australia: Australian subsidiary of a diversified life sciences group with a strong cardiology, women's health, and specialty medicine portfolio, comparable as a broad incumbent competing in Servier's therapeutic categories.
• Sanofi Australia: Australian affiliate of a top-tier global pharmaceutical company with deep presence in cardiology, diabetes, and rare disease, overlapping with Servier's cardiometabolic and specialty care franchises.
• Pfizer Australia: Australian affiliate of the largest global pharmaceutical company, offering scale, portfolio breadth, and HCP engagement capabilities that set the competitive bar for Servier Australia's sales-led model.
• AstraZeneca Australia: Australian subsidiary of a global pharmaceutical company with leading cardiovascular, oncology, and respiratory portfolios that compete directly with Servier across its core therapy areas.
• Novartis Australia: Australian operations of a global pharmaceutical major with significant cardiovascular, neuroscience, and oncology portfolios that intersect with Servier's four therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/servieraustralia
• LinkedInlinkedin.com/company/servier-australia

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Australia